Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more
Aarti Drugs Limited (AARTIDRUGS) - Total Assets
Latest total assets as of September 2025: ₹26.12 Billion INR
Based on the latest financial reports, Aarti Drugs Limited (AARTIDRUGS) holds total assets worth ₹26.12 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aarti Drugs Limited - Total Assets Trend (2006–2025)
This chart illustrates how Aarti Drugs Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Aarti Drugs Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Aarti Drugs Limited's total assets of ₹26.12 Billion consist of 52.0% current assets and 48.0% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 0.3% |
| Accounts Receivable | ₹7.52 Billion | 29.2% |
| Inventory | ₹4.73 Billion | 18.4% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹71.50 Million | 0.3% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Aarti Drugs Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aarti Drugs Limited's current assets represent 52.0% of total assets in 2025, an increase from 49.1% in 2006.
- Cash Position: Cash and equivalents constituted 0.3% of total assets in 2025, down from 0.5% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 6.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 29.2% of total assets.
Aarti Drugs Limited Competitors by Total Assets
Key competitors of Aarti Drugs Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Aarti Drugs Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Aarti Drugs Limited generates 0.93x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Aarti Drugs Limited generates $6.53 in net profit.
Aarti Drugs Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.68 | 1.61 | 1.64 |
| Quick Ratio | 1.08 | 1.01 | 1.08 |
| Cash Ratio | 0.01 | 0.02 | 0.00 |
| Working Capital | ₹5.30 Billion | ₹ 4.75 Billion | ₹ 4.09 Billion |
Aarti Drugs Limited - Advanced Valuation Insights
This section examines the relationship between Aarti Drugs Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.31 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 5.9% |
| Total Assets | ₹25.75 Billion |
| Market Capitalization | $152.86 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aarti Drugs Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Aarti Drugs Limited's assets grew by 5.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Aarti Drugs Limited (2006–2025)
The table below shows the annual total assets of Aarti Drugs Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹25.75 Billion | +5.85% |
| 2024-03-31 | ₹24.32 Billion | +0.45% |
| 2023-03-31 | ₹24.21 Billion | +9.67% |
| 2022-03-31 | ₹22.08 Billion | +25.02% |
| 2021-03-31 | ₹17.66 Billion | +12.02% |
| 2020-03-31 | ₹15.77 Billion | +7.77% |
| 2019-03-31 | ₹14.63 Billion | +5.40% |
| 2018-03-31 | ₹13.88 Billion | +17.88% |
| 2017-03-31 | ₹11.77 Billion | +6.82% |
| 2016-03-31 | ₹11.02 Billion | +10.01% |
| 2015-03-31 | ₹10.02 Billion | +17.91% |
| 2014-03-31 | ₹8.50 Billion | +18.07% |
| 2013-03-31 | ₹7.20 Billion | +17.48% |
| 2012-03-31 | ₹6.13 Billion | +17.03% |
| 2011-03-31 | ₹5.23 Billion | +24.91% |
| 2010-03-31 | ₹4.19 Billion | +3.93% |
| 2009-03-31 | ₹4.03 Billion | -3.22% |
| 2008-03-31 | ₹4.17 Billion | +13.74% |
| 2007-03-31 | ₹3.66 Billion | -0.31% |
| 2006-03-31 | ₹3.67 Billion | -- |